Moving away from amyloid beta to move on in Alzheimer research

María G. Moreno-Treviño, Jesús Castillo-López, Irene Meester

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)


Alzheimer's disease (AD) is characterized by a progressive decay of cognitive abilities, most remarkably (spatial) memory and learning. AD is diagnosed by clinical mental tests, often combined with the detection of neurobiological markers, mainly brain imaging studies and a decreased amyloid beta (Aß) level and/or increased total and hyper-phosphorylated Tau protein (tau-P) in cerebral spinal fluid (Hampel et al., 2008; Alzheimer's Association, 2014). The diagnosis is confirmed post-mortem by histopathological detection of senile plaques, composed of Aß accumulations, and tau-P-containing neurofibrillary tangles (Jellinger and Bancher, 1998). However, non-demented, aged patients may have a histopathology that is indistinguishable from AD (Price and Morris, 1999; Nelson et al., 2012). Furthermore, the brains of AD may have additional changes, such as (micro)vascular changes (Scheibel et al., 1989; de la Torre, 2002; Bell and Zlokovic, 2009; Hommet et al., 2011), white matter hyperintensities (Kandiah et al., 2015), and vacuolar cells, which are not considered as pathognomonic features under current standards (Nelson et al., 2012).

Original languageEnglish
Article number2
JournalFrontiers in Aging Neuroscience
Issue numberJAN
Publication statusPublished - 1 Jan 2015

All Science Journal Classification (ASJC) codes

  • Ageing
  • Cognitive Neuroscience


Dive into the research topics of 'Moving away from amyloid beta to move on in Alzheimer research'. Together they form a unique fingerprint.

Cite this